specific CD4 T-cell clones for both drugs. Interferon-γ/granzyme B secretion are dosedependent and drug-specific and require the presence of both soluble drug and antigenpresenting cells. Finally, blocking experiments demonstrate that the CD4 + T-cell response is major histocompatibility complex class II restricted. Existing human leucocyte antigen (HLA) data is minimal in relation to anti-TB drugs. There has been an association reported in Korean patients with DRESS for the class I allele HLA-C*04:01, 7 which extends to the haplotype HLA-A* 11:01-B*15:01-C*04:01. However, these alleles are not reported in the cases presented by Ye et al., 1 providing evidence that other class II HLA alleles may be important.
Future work is required to confirm multiple drug hypersensitivity in patients on ATD therapy suggested by the data of Ye et al. 1 and the mechanism of HLA-drug-CD4 + T-cell interactions and where possible testing strategies including genetic, in vivo approaches and ex vivo assays to support safe oral challenge should be incorporated into prospective trial designs where standardized phenotyping and testing procedures can be applied. The ability to accurately confirm the causative drug in ATD-induced ADRs will allow safer management and critical continuation of the therapy required for the efficacious treatment of TB, particularly for patients who are HIV-positive.
